Translational Development Acquisition Corp.
TDAC
$10.72
$0.010.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 281.20K | 162.30K | 213.70K | 221.10K | 347.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 281.20K | 162.30K | 213.70K | 221.10K | 347.40K |
| Operating Income | -281.20K | -162.30K | -213.70K | -221.10K | -347.40K |
| Income Before Tax | 1.33M | 1.60M | 1.66M | 1.62M | 1.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.33M | 1.60M | 1.66M | 1.62M | 1.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.33M | 1.60M | 1.66M | 1.62M | 1.48M |
| EBIT | -281.20K | -162.30K | -213.70K | -221.10K | -347.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.29 | 0.07 | 0.08 | 0.07 | 0.32 |
| Normalized Basic EPS | 0.18 | 0.04 | 0.05 | 0.05 | 0.20 |
| EPS Diluted | 0.29 | 0.07 | 0.08 | 0.07 | 0.32 |
| Normalized Diluted EPS | 0.18 | 0.04 | 0.05 | 0.05 | 0.20 |
| Average Basic Shares Outstanding | 4.66M | 21.91M | 21.91M | 21.91M | 4.66M |
| Average Diluted Shares Outstanding | 4.66M | 21.91M | 21.91M | 21.91M | 4.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |